The National Advertising Division on Thursday recommended that Church & Dwight discontinue its claim that the company’s First Response digital ovulation test is the “first and only test to predict ovulation based on your unique LH hormone level.”
A study slated to appear in the Journal of Clinical Endocrinology & Metabolism, a publication of the Endocrine Society, found that adolescent girls that take the diabetes drug metformin may prevent or delay the development of polycystic ovary syndrome, a common cause of infertility.
Many American consumers are in favor of oral contraceptive coverage by both private and government-subsidized health insurance plans, according to a Thomson Reuters-National Press Radio Health Poll released Friday.
Church & Dwight in April launched the First Response Digital Ovulation Test, a new at-home ovulation test that can detect a woman’s personal luteinizing hormone surge — the hormonal indication of ovulation — based on her own individual hormone levels.
Church & Dwight on Tuesday announced the launch of its First Response digital ovulation test, a new at-home ovulation test that can detect a woman's personal luteinizing hormone, or LH, surge — the hormonal indication of ovulation — based on her own individual hormone levels.
The National Advertising Division of the Council of Better Business Bureaus last week recommended that SPD Swiss Precision Diagnostics, manufacturer of the Clearblue Easy Digital home pregnancy test, modify its advertising to clarify to consumers that the test only delivers completely “certain” results on or after the day of a consumer’s expected menstrual period.
The Food and Drug Administration has approved the first and only low-dose oral contraceptive to combine 0.8-mg norethindrone and 0.025-mg ethinyl estradiol in a chewable form, with four 75-mg ferrous fumarate (iron) placebo tablets, Watson Pharmaceuticals has announced.